logo-loader
Ergomed PLC

Ergomed plc - Award of share options

RNS Number : 3455T
Ergomed plc
03 July 2018
 

PRESS RELEASE

 

Ergomed award of share options to Directors and Company Secretary

 

London, UK - 3 July 2018: Ergomed plc, (LSE:ERGO) ("Ergomed" or the "Company")  a company focused on providing specialised services to the pharmaceutical industry, today announces that the following LTIP (Long Term Investment Plan) awards have been made to newly-appointed CFO Stuart Jackson, COO Jan Petracek, and General Counsel and Company Secretary Sanja Juric.

 

The awards consist of share options over the Company's ordinary shares having a nominal value of 1 pence each (the "Options") with an exercise price of 1 pence per share.  Of the total, 50% of the Options will vest after three years and are not subject to performance criteria. The remaining 50% will vest based on total shareholder return over the three year vesting period with a minimum of 15 per cent. per annum. Once vested the options will be exercisable until 1 July 2028.

 

Director / Executive

Award of Options

Resulting interest in options

Current shareholding in the Company

Stuart Jackson,

Chief Financial Officer

400,000

400,000

1,845

Jan Petracek, Chief Operations Officer

400,000

450,000

418,006

Sanja Juric, General Counsel and Company Secretary *

25,000

175,000

Nil

 

* Sanja Juric also holds 150,000 options over shares owned by Dr Miroslav Reljanovic.

 

In total 825,000 Options were granted yesterday, representing 1.8 per cent. of the issued share capital.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

1)   Stuart Jackson

2)   Jan Petracek

3)   Sanja Juric

2

Reason for the notification

a)

Position/status

1)   Chief Financial Officer

2)   Chief Operations Officer

3)   General Counsel and Company Secretary

b)

Initial notification /Amendment

1)   Initial Notification

2)   Initial Notification

3)   Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ergomed Plc

b)

Legal Entity Identifier

213800BVS8I9VMC1AP84

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 GB00BN7ZCY67

b)

Nature of the transaction

Award of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

1)   Nil

400,000

2)   Nil

450,000

3)   Nil

175,000


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

1) 400,000 ordinary shares of 1 pence each, nil consideration

2) 450,000 ordinary shares of 1 pence each, nil consideration

3) 175,000 ordinary shares of 1 pence each, nil consideration

f)

Date of the transaction

03 July 2018

g)

Place of the transaction

Outside a trading venue

 

ENDS

 



 

Enquiries:

 

Ergomed plc

Tel: +44 (0) 1483 503 205

Stephen Stamp (Chief Executive Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)


James Black (Joint Broker)




N+1 Singer

Tel: +44 (0) 20 7496 3000

Aubrey Powell (Joint Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Olivia Manser

ergomed@consilium-comms.com



MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSSIEFEFASEDW
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Ergomed in robust shape to keep delivering

Jonathan Curtain, the new CFO of Ergomed PLC (AIM:ERGO, ETR:2EM), discussed his background and the company's growth prospects in an interview with Proactive London. The specialist services provider to the pharmaceutical industry focuses on growth areas like rare diseases and...

on 17/5/23

3 min read